Chemistry:Clevudine
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C10H13FN2O5 |
| Molar mass | 260.221 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines . It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.
Researchers in South Korea are testing clevudine at lower doses in combination with adefovir for continued use.[2]
It is a nucleoside analog.[3]
References
- ↑ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL.
- ↑ "A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.". Hepatology International 8 (3): 375–381. May 2014. doi:10.1007/s12072-014-9537-5. PMID 25101150.
- ↑ "A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B". Hepatology 43 (5): 982–8. May 2006. doi:10.1002/hep.21166. PMID 16628625.
 |  |
